204 related articles for article (PubMed ID: 11687543)
1. Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy.
Berkowitz BA; Ito Y; Kern TS; McDonald C; Hawkins R
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2964-9. PubMed ID: 11687543
[TBL] [Abstract][Full Text] [Related]
2. Subnormal retinal oxygenation response precedes diabetic-like retinopathy.
Berkowitz BA; Kowluru RA; Frank RN; Kern TS; Hohman TC; Prakash M
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2100-5. PubMed ID: 10440266
[TBL] [Abstract][Full Text] [Related]
3. Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.
Berkowitz BA; Roberts R; Luan H; Peysakhov J; Knoerzer DL; Connor JR; Hohman TC
Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2954-60. PubMed ID: 16043871
[TBL] [Abstract][Full Text] [Related]
4. Blocking ET-1 receptors does not correct subnormal retinal oxygenation response in experimental diabetic retinopathy.
Roberts R; Luan H; Berkowitz BA
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3550-5. PubMed ID: 16877428
[TBL] [Abstract][Full Text] [Related]
5. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.
Kern TS; Tang J; Mizutani M; Kowluru RA; Nagaraj RH; Romeo G; Podesta F; Lorenzi M
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3972-8. PubMed ID: 11053301
[TBL] [Abstract][Full Text] [Related]
6. Retinal thickness and subnormal retinal oxygenation response in experimental diabetic retinopathy.
Luan H; Roberts R; Sniegowski M; Goebel DJ; Berkowitz BA
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):320-8. PubMed ID: 16384980
[TBL] [Abstract][Full Text] [Related]
7. Galactose-induced retinal microangiopathy in rats.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
[TBL] [Abstract][Full Text] [Related]
8. Significant reduction of the panretinal oxygenation response after 28% supplemental oxygen recovery in experimental ROP.
Berkowitz BA; Zhang W
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1925-31. PubMed ID: 10845618
[TBL] [Abstract][Full Text] [Related]
9. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Frank RN; Amin R; Kennedy A; Hohman TC
Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
[TBL] [Abstract][Full Text] [Related]
10. Effect of PKCbeta on retinal oxygenation response in experimental diabetes.
Luan H; Leitges M; Gupta RR; Pacheco D; Seidner A; Liggett J; Ito Y; Kowluru R; Berkowitz BA
Invest Ophthalmol Vis Sci; 2004 Mar; 45(3):937-42. PubMed ID: 14985314
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging retinal oximetry: a quantitative physiological biomarker for early diabetic retinopathy?
Yang Y; Zhu XR; Xu QG; Metcalfe H; Wang ZC; Yang JK
Diabet Med; 2012 Apr; 29(4):501-5. PubMed ID: 21913965
[TBL] [Abstract][Full Text] [Related]
12. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
Agardh E; Hultberg B; Agardh C
Curr Eye Res; 2000 Jul; 21(1):543-9. PubMed ID: 11035534
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of retinal metabolism in diabetes or galactosemia: ATPases and glutathione.
Kern TS; Kowluru RA; Engerman RL
Invest Ophthalmol Vis Sci; 1994 Jun; 35(7):2962-7. PubMed ID: 8206713
[TBL] [Abstract][Full Text] [Related]
14. Termination of experimental galactosemia in rats, and progression of retinal metabolic abnormalities.
Kowluru RA; Koppolu P
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3287-91. PubMed ID: 12356836
[TBL] [Abstract][Full Text] [Related]
15. alpha-lipoic acid corrects late-phase supernormal retinal oxygenation response in experimental diabetic retinopathy.
Roberts R; Luan H; Berkowitz BA
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4077-82. PubMed ID: 16936127
[TBL] [Abstract][Full Text] [Related]
16. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine.
Kowluru RA; Engerman RL; Kern TS
Curr Eye Res; 2000 Oct; 21(4):814-9. PubMed ID: 11120572
[TBL] [Abstract][Full Text] [Related]
17. Early supernormal retinal oxygenation response in patients with diabetes.
Trick GL; Edwards P; Desai U; Berkowitz BA
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1612-9. PubMed ID: 16565400
[TBL] [Abstract][Full Text] [Related]
18. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the early subnormal retinal oxygenation response in experimental diabetes by inducible nitric oxide synthase.
Berkowitz BA; Luan H; Gupta RR; Pacheco D; Seidner A; Roberts R; Liggett J; Knoerzer DL; Connor JR; Du Y; Kern TS; Ito Y
Diabetes; 2004 Jan; 53(1):173-8. PubMed ID: 14693712
[TBL] [Abstract][Full Text] [Related]
20. Specificity of subnormal deltaPO2 for retinal neovascularization in experimental retinopathy of prematurity.
Zhang W; Ito Y; Berlin E; Roberts R; Luan H; Berkowitz BA
Invest Ophthalmol Vis Sci; 2003 Aug; 44(8):3551-5. PubMed ID: 12882806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
